Home > Novartis' canakinumab doesn't meet primary endpoint in phase III study
Novartis' canakinumab doesn't meet primary endpoint in phase III study
Info
Access Option
News Date
2021-03-09
Newspaper
Business Recorder
Editor
M. A. Zuberi
Newspaper Country
Pakistan
Newspaper City
Karachi
Newspaper Website
Newspaper Languages
en
Newspaper Frequency
Daily
ARI ID
1692442401131
Similar
Similar News
Loading...
Similar Articles
Loading...
Similar Article Headings
Loading...
Similar Thesis
Loading...